Overview

A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants

Status:
Not yet recruiting

Trial end date:
2024-05-16

Target enrollment:

Participant gender:

Summary

This is an open-label, dose-escalation study to investigate the safety, tolerability, and pharmacokinetics (PK) of single subcutaneous (SC) administration of long acting (LA) CAB200 or CAB400 with Recombinant Human Hyaluronidase PH20 (rHuPH20) (Parts A or B respectively).

Phase:

Phase 1

Details

Lead Sponsor:

ViiV Healthcare

Treatments:

Cabotegravir